Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN 70 30 versus HUMULIN R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN 70 30 versus HUMULIN R.
HUMULIN 70/30 vs HUMULIN R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin replacement therapy. Human insulin is a recombinant DNA-derived polypeptide hormone that regulates glucose metabolism. Insulin binds to the insulin receptor, activating tyrosine kinase activity, which leads to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis and lipogenesis.
Human insulin is identical to endogenous insulin. It binds to insulin receptors on target cells, activates tyrosine kinase signaling, and promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis while inhibiting gluconeogenesis and glycogenolysis.
Subcutaneous injection, 0.5-1.0 units/kg/day divided into two doses (before breakfast and before dinner), adjusted based on blood glucose monitoring.
Subcutaneous: 0.2-0.6 units/kg/day divided into 2-3 doses, individualized. Intravenous: Insulin infusion protocols for hyperglycemia.
None Documented
None Documented
0.5-1 hour (free insulin); 8-12 hours (prolonged due to NPH component, reflecting duration of action).
Terminal elimination half-life: 0.5-1 hour (intravenous); prolonged in renal impairment (up to 3-4 hours).
Renal: 100% (metabolized to inactive fragments; negligible excretion of intact insulin).
Primarily renal (>90% as unchanged drug after degradation), with minor biliary/fecal elimination (<10%).
Category C
Category C
Human Insulin
Human Insulin